Factors Impelling Growth of Cell Therapy Manufacturing Market through 2026 and Beyond

Cell therapy is one of the most promising healthcare procedure for restoration of damaged tissue. Cell therapies have huge potential for the wide range of disease treatment including tissue degradation, immune deficiency, metabolic disorders, and cancer. Cell therapy are categorized into two type’s allogeneic (cells from third party donor) and autologous (cells from one’s own body). Cell therapy has gained significant traction in recent past and currently it under commercial development. Main objective of cell therapy is to re-establish the lost function of tissues and cells rather than to produce a new organ. Some cell therapies have been established and permitted for clinical trial. For instance, in 2013 a stage 2 clinical trial was completed for transplantation of bone marrow derived stem cells in affected knee by rheumatoid arthritis. The growth of this technique is also increased due to involvement of the government agencies. For instance, innovate U.K. 2014 report showed that government agreed to fund US$15.3 million in cell therapy manufacturing market.

Request For Customization @  https://www.coherentmarketinsights.com/insight/request-customization/1728

Cell Therapy Manufacturing Market Dynamics:

Increasing number of surgical procedures performed across the world coupled with increasing number of trauma and accidents is propelling demand for new medical therapy. For instance, according to a 2015, World Health Organization (WHO) report, more than 50,000 stem cell transplants are carried out annually worldwide for various surgeries. Stem cells transplantation is promising medical therapy for patients with advance stage diseases like Alzheimer’s, arthritis, autism, blindness, cancer, cerebral palsy, diabetes etc. Key biopharmaceutical companies are majorly investing in research for cell therapy. For instance, Longeveron LL, a biopharmaceutical company received a US$ 750,000 grant from the Maryland Technology Development Corporation (TEDCO) in 2018 for stem cell therapy research. These collaborations and government funding are boosting growth of the cell therapy manufacturing market. However, the strict regulations, guidelines, and various health safety concerns over cell therapy treatment are restraining growth of the cell therapy market.

Cell Therapy Manufacturing Market - Regional Insights:

On the basis of the region, the global cell therapy market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America holds the dominant position in the global cell therapy manufacturing market, owing to large number of surgeries performed in the region as well as development of technologically advanced products for therapy. According to the National Health Statistics Report by the Centers for Disease Control & Prevention (CDC), around 201,748.3 million surgical and non-surgical procedures were performed in the U.S. in 2011.

Asia Pacific is projected to witness significant growth in the global cell therapy manufacturing market in the near future. Marginal market share would be grabbed by the local players entering into market due to less stringent regulatory requirements and growing customer pool prone to various chronic and infectious disease such as cancer, HIV, hepatitis etc. Therefore induction of cell therapy can provide better solutions to the patient at the marginally lower cost.

For More Information @ https://www.coherentmarketinsights.com/ongoing-insight/cell-therapy-manufacturing-market-1728

Cell Therapy Manufacturing Market - Competitive Insights:

The key player operating in the global cell therapy manufacturing market include, Pharmicell, Merck Group, Dickinson and Company, Thermo Fisher, Lonza Group, Miltenyi Biotec GmBH, Takara Bio Group, STEMCELL Technologies, Cellular Dynamics International, Becton, Osiris Therapeutics, Bio-Rad Laboratories, Inc., Anterogen, MEDIPOST, Holostem Terapie Avanazate, Pluristem Therapeutics, Brammer Bio, CELLforCURE, Gene Therapy Catapult EUFETS, MaSTherCell, PharmaCell, Cognate BioServices and WuXi AppTec. Key players are adoption growth strategies such as collaborations, introduction of new technologies and devices to maintain dominant position in the market. For instance, in 2014, ViaCyte, Inc. successfully implanted VC-01 an embryonic stem cell derived islet for the treatment of type 1 diabetes. 

Cell Therapy Manufacturing Market Taxonomy:

On the basis of therapy type, the global cell therapy manufacturing market is segmented into:
• Allogeneic Cell Therapy
• Autologous Cell Therapy

On the basis of technology, the global cell therapy manufacturing market is segmented into:
• Somatic Cell Technology
• Cell Immortalization Technology
• Viral Vector Technology
• Genome Editing Technology
• Cell Plasticity Technology
• 3D Technology

On the basis of source, the global cell therapy manufacturing market is segmented into:
• IPSC’s (Induced pluripotent stem cell)
• Bone marrow
• Umbilical cord
• Adipose tissue
• Neural stem

On the basis of application, the global cell therapy manufacturing market is segmented into:
• Musculoskeletal
• Cardiovascular
• Gastrointestinal
• Neurological
• Oncology
• Dermatology
• Others

On the basis of region, the global cell therapy manufacturing market is segmented into:
• North America
• Latin America
• Europe
• Asia Pacific
• Middle East
• Africa

Download PDF Brochure Of This Research Report @ www.coherentmarketinsights.com/insight/request-pdf/1728

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us: 

Mr. Shah
Coherent Market Insights
1001 4th Ave, 
#3200 
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

This release was published on openPR.